Piramal Pharma Limited has informed the Exchange regarding Mr. Subramanian Ramadorai cessation as an Independent Director of the Company with effect from 9th February, 2026.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has informed the stock exchange that Mr. Subramanian Ramadorai will cease to be an Independent Director of the company with effect from 9th February 2026. Mr. Ramadorai is a well-known industry figure, having previously served as Chairman of TCS. The filing does not specify the reason for cessation, which typically indicates completion of a board term or a planned exit. No details on his replacement or any change in board committee composition have been provided in this filing. Shareholders will likely await a separate announcement regarding the appointment of a new Independent Director to maintain statutory board composition.
This is a routine board-level change with limited direct impact on stock price or operations. Investors may watch for the appointment of a new Independent Director to ensure continued compliance with SEBI's board composition norms. No material business disruption is expected.